Triple receptor agonist — the most powerful and muscle-sparing compound in the GLP-1 family
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It delivers the strongest appetite suppression and broadest metabolic improvement in the GLP-1 family, while being the most muscle-sparing GLP-1 compound available.
Activates three key metabolic receptors: GLP-1 (appetite suppression, insulin sensitivity), GIP (nutrient partitioning, fat metabolism), and glucagon (energy expenditure, fat oxidation). This triple-agonist approach covers multiple metabolic pathways in a single compound.
| Parameter | Details |
|---|---|
| Starting Dose | 1–2 mg/week |
| Moderate Dose | 4–6 mg/week |
| High Dose | 10–12 mg/week |
| Frequency | Daily injection preferred |
| Cycle Length | 8–16 weeks |
| Route | Subcutaneous (SubQ) daily |
| Storage | Refrigerate, use within 4–6 months |
GLP-1 Titration Protocol
Increase by 0.25 mg weekly increments to minimize gastrointestinal adverse effects. Do not rush titration.
Stacking Warning
Do NOT stack with other fat-loss peptides — Retatrutide already covers multiple metabolic pathways.
FDA Black-Box Warning
FDA black-box warning exists across the entire GLP-1 class regarding thyroid C-cell tumors observed in rodent studies. No confirmed human signal. Prescriber authorization required.
Clinical Note
Monitor body composition (not just scale weight), blood glucose, lipid panel, and GI tolerance. Prescriber authorization required for dose changes.
This guide is for educational and clinical-support purposes only. All dosing must be supervised by a licensed prescriber. Matrix Advanced Solutions does not provide medical advice. Always consult your healthcare provider before starting any peptide protocol.